The value of innovation report by the Decision Support Unit
The aim of this review is to provide an overview of how innovation is currently valued in the UK health system and the potential initiatives that can be adopted in order to promote innovation in the NHS. The report includes a review of the scientific, policy and economic literature. The key findings...
| Main Authors: | , , , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
London
National Institute for Health and Care Excellence (NICE)
22 May 2009, 2009
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The aim of this review is to provide an overview of how innovation is currently valued in the UK health system and the potential initiatives that can be adopted in order to promote innovation in the NHS. The report includes a review of the scientific, policy and economic literature. The key findings are that the NICE approach to appraisal offers the opportunity and incentive for manufacturers to appropriate the full value of innovation during patent protection. This aligns incentives for investment in research and development with the needs of the NHS and the budget constraint it faces. Although there are potential future benefits of innovation, the case that NICE should anticipate these future benefits and reward them before they have been realised is not well supported and could lead to the NHS paying twice for future benefits and distorting incentives for future innovations. There is a case that the existing measures of health benefit used by NICE may not capture all aspects of health and non-health outcomes that might be regarded and socially valuable. This is already recognised in the appraisal process and in the considerations of the appraisal committee. These other aspects of benefit are not specific to innovations (new technologies) but are also relevant to all NHS and other public health interventions. Any amendment to the measurement of health benefit as well as other non-health aspects of benefit is part of a debate which is wider than the specific question of valuing innovation. It also suggests that demonstrating that a technology offers other aspects of benefit outside measures of quality of life is not sufficient. There would also need to be a demonstration that they exceed the other aspects benefits that are likely to be forgone elsewhere in the NHS due to the additional costs of the technology |
|---|---|
| Physical Description: | 1 PDF file (47 pages) illlustrations |